# Curatis Holding AG

> Curatis Holding AG (SIX:CURN) announcements published on FAQSIR. AI-generated content. Paid-for issuer communication. Not investment advice.

canonical: https://faqsir.com/company/curatis-holding-ag
generated_at: 2026-10-21T09:49:28+00:00

## Company

- Name: Curatis Holding AG
- Listings: SIX:CURN
- Also known as: Curatis, Curatis AG,, Curatis Group
- Website: https://curatis.com/

## Disclosure

- AI-generated content: This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording.
- Unpaid evaluation: The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage.
- Not investment advice: This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.
- Grounding: Content is generated from the company's published announcements.
- Disclosure version: 2026.09.3

## Endpoints

- [Company hub](https://faqsir.com/company/curatis-holding-ag): the Curatis Holding AG announcements listed below, as a page
- [Latest announcement](https://faqsir.com/company/curatis-holding-ag/latest): redirects to the newest release, or to the hub when there is no recent one
- [Atom feed](https://faqsir.com/company/curatis-holding-ag/feed): the latest 50 releases, as Atom
- [JSON feed](https://faqsir.com/company/curatis-holding-ag/feed.json): the latest 50 releases, as JSON Feed 1.1
- [Site-wide llms.txt](https://faqsir.com/llms.txt): what this site publishes beyond this issuer

## Releases

Every announcement this hub lists: 7 announcements, newest first. Each URL is that release's canonical URL.

- 2026-09-21 — [Curatis reports 51% first-half revenue increase and progress on corticorelin programme](https://faqsir.com/company/curatis-holding-ag/curatis-reports-51-first-half-revenue-increase-and-progress-on-corticorelin-programme): Curatis Holding AG reported higher first-half sales, improved its operating result and advanced development of corticorelin, including an exclusive Japan licence with Neupharma.
- 2026-06-11 — [Curatis raises 2026 revenue growth guidance to approximately 40%](https://faqsir.com/company/curatis-holding-ag/curatis-raises-2026-revenue-growth-guidance-to-approximately-40): Curatis Holding AG has lifted its 2026 revenue growth outlook to approximately 40%, citing preliminary results from the first five months of the year.
- 2026-05-22 — [Curatis Holding AG shareholders approve all board proposals at AGM](https://faqsir.com/company/curatis-holding-ag/curatis-holding-ag-shareholders-approve-all-board-proposals-at-agm): Curatis Holding AG shareholders approved all Board of Directors proposals at the company’s Annual General Meeting in Liestal, Switzerland, on 22 May 2026.
- 2026-05-22 — [Curatis agrees CHF 3.0 million convertible placement, subject to closing conditions](https://faqsir.com/company/curatis-holding-ag/curatis-agrees-chf-30-million-convertible-placement-subject-to-closing-conditions): Curatis Holding AG has signed a definitive agreement for a CHF 3.0 million convertible instrument with a strategic Swiss investor. The transaction remains subject to customary closing conditions.
- 2026-03-24 — [Curatis reports 2025 revenue growth as corticorelin programme advances](https://faqsir.com/company/curatis-holding-ag/curatis-reports-2025-revenue-growth-as-corticorelin-programme-advances): Curatis Holding AG reported higher 2025 revenues, a reduced net loss and progress on its corticorelin programme, including a Japan licensing agreement with Neupharma.
- 2026-03-11 — [Curatis and Neupharma announce Japan licensing agreement for corticorelin](https://faqsir.com/company/curatis-holding-ag/curatis-and-neupharma-announce-japan-licensing-agreement-for-corticorelin): Curatis Holding AG and Neupharma have announced an exclusive agreement covering the development and commercialisation of corticorelin for peritumoral brain edema in Japan.
- 2025-11-21 — [Curatis agrees CHF 1.2 million convertible placement, subject to conditions](https://faqsir.com/company/curatis-holding-ag/curatis-agrees-chf-12-million-convertible-placement-subject-to-conditions): Curatis Holding AG has agreed a CHF 1.2 million private placement of a convertible instrument with a strategic Swiss investor. The transaction is expected to close within the next few days, subject to...